Chapter 17 Botulinum toxin mechanisms of action

Supplements to Clinical Neurophysiology

Volumn 57, Issue C, 2004, Pages 159-166

  Dressler, Dirk ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN;

ANIMAL; AUTONOMIC NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM; DOSE RESPONSE; DRUG EFFECT; ELECTROMYOGRAPHY; HUMAN; MOLECULAR WEIGHT; MYOTATIC REFLEX; PHYSIOLOGY; REACTION TIME; REVIEW; SKELETAL MUSCLE; TIME;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; BOTULINUM TOXINS; CENTRAL NERVOUS SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROMYOGRAPHY; HUMANS; MOLECULAR WEIGHT; MUSCLE, SKELETAL; REACTION TIME; REFLEX, STRETCH; TIME FACTORS;

EID: 25144484330     PISSN: 1567424X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1567-424X(09)70353-8     Document Type: Article

References (42)

1. Blasi J., Chapman E.R., Link E., et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365 (1993) 160-163
2. Ceballos-Baumann A.O., Sheean G., Passingham R.E., et al. Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study. Brain 120 (1997) 571-582
3. Cuesta M., Arcaya J., and Cano G. Opposite modulation of capsaicin-evoked substance P release by glutamate receptors. Neurochem. Int. 35 (1999) 471-478
4. Cui M., and Aoki K.R. Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalalgia 20 (2000) 414
5. Cui, M., Li, S., Khanijou, S. and Aoki, K. Subcutaneous BOTOX inhibits formalin-induced local neurotransmitter release and spinal nociceptive processing. Presented at the 10th World Congress on Pain. August, 2002a.
6. Cui M., Li Z., You S., Khanijou S., and Aoki R. Mechanisms of the antinociceptive effect of subcutaneous Botox: inhibition of peripheral and central nociceptive processing. Abstracts of the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Naunyn-Schmiedeberg's Arch. Pharmacol. 365 (2002) R17
7. De Paiva A., Meunier F.A., Molgo J., Aoki K.R., and Dolly J.O. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl. Acad. Sci. USA 96 (1999) 3200-3205
8. Dressler D. Botulinum toxin therapy failure: causes, evaluation procedures and management strategies. Eur. J. Neurol. 4 Suppl. 2 (1997) S67-S70
9. Dressler D. Botulinum Toxin Therapy (2000), Thieme, Stuttgart
10. Dressler D. Dysport produces intrinsically more swallowing problems than Botox: Unexpected results from a conversion factor study in cervical dystonia. J. Neurol. Neurosurg. Psychiatry 73 (2002) 604
11. Dressler D., and Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur. Neurol. 49 (2003) 34-38
12. Dressler D., and Rothwell J.C. Electromyographic quantification of the paralysing effect of botulinum toxin. Eur. Neurol. 43 (2000) 13-16
13. Dressler D., Eckert J., Kukowski B., and Meyer B. Somatosensory evoked potentials in writer's cramp: Pathological findings reversed by botulinum toxin therapy. EEG Clin. Neurophysiol. 94 (1995) 59P
14. Filippi G.M., Errico P., Santarelli R., Bagolini B., and Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 113 (1993) 400-404
15. Gilio F., Curra A., Lorenzano C., Modugno N., Manfredi M., and Berardelli A. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann. Neurol. 48 (2000) 20-26
16. Girlanda P., Vita G., Nicolosi C., Milone S., and Messina C. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J. Neurol. Neurosurg. Psychiatry 55 (1992) 844-845
17. Hagenah R., Benecke R., and Wiegand H. Effects of type A botulinum toxin on the cholinergic transmission at spinal Renshaw cells and on the inhibitory action at Ia inhibitory interneurones. Naunyn Schmiedebergs Arch. Pharmacol. 299 (1977) 267-272
18. Ishikawa H., Mitsui Y., Yoshitomi T., Mashimo K., Aoki S., Mukuno K., and Shimizu K. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn. J. Ophthalmol. 44 (2000) 106-109
19. Kaji R., Rothwell J.C., Katayama M., Ikeda T., Kubori T., Kohara N., Mezaki T., Shibasaki H., and Kimura J. Tonic vibration reflex and muscle afferent block in writer's cramp. Ann. Neurol. 38 (1995) 155-162
20. Kaji R., Kohara N., Katayama M., Kubori T., Mezaki T., Shibasaki H., and Kimura J. Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp. Muscle Nerve 18 (1995) 234-235
21. Kerner, J. Neue Beobachtungen über die in Württemberg so häufig vorfallenden tödlichen Vergiftungen durch den Genuss geräucherter, Würste. Osiander, Tübingen, 1820.
22. Kerner, J. Das Fettgift oder die Fettsäure und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Cotta, Stuttgart, Tübingen, 1822.
23. Lange D.J., Brin M.F., Warner C.L., Fahn S., and Lovelace R.E. Distant effects of local injection of botulinum toxin. Muscle Nerve 10 (1987) 552-555
24. Ludlow C.L., Hallett M., Sedory S.E., Fujita M., and Naunton R.F. The pathophysiology of spasmodic dysphonia and its modification by botulinum toxin. In: Berardelli A., Benecke R., Manfredi M., and Marsden C.D. (Eds). Motor Disturbances II (1990), Academic Press, New York 273-288
25. McMahon H., Foran P., and Dolly J. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes: clues to the locus of action. J. Biol. Chem. 267 (1992) 21338-21343
26. Modugno N., Priori A., Berardelli A., Vacca L., Mercuri B., and Manfredi M. Botulinum toxin restores presynaptic inhibition of group Ia afferents in patients with essential tremor. Muscle Nerve 21 (1998) 1701-1705
27. Moreno-Lopez B., Dela Cruz R.R., Pastor A.M., and Delgado-Garcia J.M. Botulinum neurotoxin alters the discharge characteristics of abducens motoneurons in the alert cat. J. Neurophysiol. 72 (1994) 2041-2044
28. Moreno-Lopez B., Pastor A.M., Dela Cruz R.R., and Delgado-Garcia J.M. Dose-dependent, central effects of botulinum neurotoxin type A: a pilot study in the alert behaving cat. Neurology 48 (1997) 456-464
29. Morris J., Jobling P., and Gibbins I. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) 2124-2132
30. Olney R.K., Aminoff M.J., Gelb D.J., and Lowenstein D.H. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 38 (1988) 1780-1783
31. Priori A., Berardelli A., Mercuri B., and Manfredi M. Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles. Brain 118 (1995) 801-807
32. Purkiss J., Welch M., Doward S., and Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem. Pharmacol. 59 (2000) 1403-1406
33. Rizo J., and Sudhof T.C. Mechanics of membrane fusion. Nat. Struct. Biol. 5 (1998) 839-842
34. Rosales R.L., Arimura K., Takenaga S., and Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19 (1996) 488-496
35. Sanders D.B., Massey E.W., and Buckley E.G. Botulinum toxin for blepharospasm: single-fibre EMG studies. Neurology 36 (1986) 545-547
36. Shone C.C., and Melling J. Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neurotoxin on intact cells. Eur. J. Biochem. 207 (1992) 1009-1016
37. Takamizawa K., Iwamori M., Kozaki S., Sakaguchi G., Tanaka R., Takayama H., and Nagai Y. TLC immunostaining characterization of Clostridium botulinum type A neurotoxin binding to gangliosides and free fatty acids. FEBS Lett. 201 (1986) 229-232
38. Urban M., and Gebhart G. Central mechanisms in pain. Med. Clin. North Am. 83 (1999) 585-596
39. Welch M.J., Purkiss J.R., and Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to clostridium botulinum neurotoxins. Toxicon 38 (2000) 245-258
40. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch. Pharmacol. 292 (1976) 161-165
41. Yoshida K., Kaji R., Kubori T., Kohara N., lizuka T., and Kimura J. Muscle afferent block for the treatment of oromandibular dystonia. Mov. Disord. 13 (1998) 699-705
42. Zwirner P., Murry T., Swenson M., and Wooodson G. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings. Laryngoscope 102 (1992) 400-406